步长制药: 山东步长制药股份有限公司第五届董事会第三十一次会议决议公告

Core Points - The company held its 31st meeting of the 5th Board of Directors on September 4, 2025, where all 9 attending directors approved several key resolutions [1] - The company plans to change the legal representatives of its subsidiaries, including Shandong Buchang Pharmaceutical Biotechnology Co., Ltd., Shandong Buchang Dingsheng Pharmaceutical Co., Ltd., and Shandong Buchang Chuanfang Pharmaceutical Co., Ltd. for operational management needs [1] - The company intends to reduce the registered capital of its wholly-owned subsidiary Jiangsu Hapu Medical Technology Co., Ltd. from 50.2 million yuan to 5 million yuan to optimize resource allocation and improve capital efficiency [2] - The company plans to deregister several subsidiaries, including Changsha Zhongce Biotechnology Co., Ltd., Hunan Zhongce Biotechnology Co., Ltd., and Buchang (Guangzhou) Medical Diagnosis Technology Co., Ltd. to lower management costs [3][4] - The company approved the transfer of shares in its subsidiaries, including a 0.50% stake in Buchang Chuanfang for 0.6875 million yuan and a 3.00% stake in Buchang Dingsheng, with the company agreeing to waive its right of first refusal [4][5] - The company will acquire a 1.50% unpaid equity stake in its subsidiary Buchang Pharmaceutical Biotechnology Co., Ltd. for 0 yuan, while also transferring 1.00% and 0.50% stakes to other individuals for 0 yuan [6]